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It has been hypothesized that sensitivity to low-level chemical exposures develops in two steps:
initiation by an acute or chronic chemical exposure, followed by triggering of symptoms by low
levels of previously tolerated chemical inhalants, foods, or drugs. The Working Group on Toxicant-
induced Loss of Tolerance has formulated a series of research questions to test this hypothesis:
Do some individuals experience sensitivity to chemicals at levels of exposure unexplained by
classical toxicological thresholds and dose-response relationships, and outside normally expected
variation in the population? Do chemically sensitive subjects exhibit masking that may interfere
with the reproducibility of their responses to chemical challenges? Does chemical sensitivity
develop because of acute, intermittent, or continuous exposure to certain substances? If so,
what substances are most likely to initiate this process? An experimental approach for testing
directly the relationship between patients' reported symptoms and specific exposures was
outlined in response to the first question, which was felt to be a key question. Double-blind,
placebo-controlled challenges performed in an environmentally controlled hospital facility
(environmental medical unit) coupled with rigorous documentation of both objective and
subjective responses are necessary to answer this question and to help elucidate the nature and
origins of chemical sensitivity. - Environ Health Perspect 105(Suppl 2):515-519 (1997)
Key words: chemical challenges, chemical exposure, chemical testing, chemical sensitivity,
environmental medical unit, exposure chamber, intolerance, multiple chemical sensitivity,
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Introduction and Definitions
It has been hypothesized that sensitivity to same substance or chemically dissimilar
low-level chemical exposures develops in substances (1-5). Possible initiators
two steps: induction or initiation by a include single, high-level exposures or
chemical exposure event, followed by trig- chronic (intermittent or continuous) lower
gering of symptoms by low levels of the level exposures. Triggers include common
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inhalants such as fragrances, traffic exhaust,
foods, drugs, alcohol, and caffeine. Although
anecdotal clinical evidence supports this
hypothesis, carefully conducted epidemio-
logic and experimental studies are needed
for its corroboration or rejection.
A series of research questions designed to
test the two-step mechanism proposed above
was devised. While other working groups
focused on conditioning and learning, psy-
choneuroimmunology, neurogenic inflam-
mation, and neural sensitization as possible
explanations for chemical sensitivity, the
Working Group on Toxicant-induced Loss
of Tolerance developed an approach to test
directly the relationship between specific
exposures and patients' reported symptoms
and physiological responses.
Double-blind, placebo-controlled human
challenge studies are essential to under-
stand the nature of chemical sensitivity.
Research focusing on exploring particular
mechanisms while excluding others at this
early stage of scientific investigation could
lead to blind alleys. Pivotal questions about
the origins of the condition, such as the
role of chemical exposures compared to
that of individual perception, may remain
unanswered. In the tradition of scientific
inquiry, research in this area should pro-
ceed from the general to the specific. Once
the general nature of chemical sensitivity is
understood (e.g., toxigenic, psychogenic),
particular mechanisms can be explored.
Scarce resources must not be expended on
intriguing but irrelevant hypotheses.
Defining whether chemical sensitivity is
physiological in origin or psychogenic is
important for many reasons, including pol-
icy setting, prevention, and selection of
appropriate therapies. However, investiga-
tors in this area must be cautious in inter-
preting their experimental observations
because subjects' responses to challenges
may involve both physiological and psy-
chological elements. For example, psycho-
logical symptoms such as depression or
irritability may be psychogenic or organi-
cally based, or both. Subjects who fail to
respond to active challenges may respond
differently under other circumstances.
Blinding odorous substances is a task
subject to numerous pitfalls.
Several terms were defined. Loss of
tolerance is defined as the loss of natural or
native tolerance for common substances
such as fragrances, traffic exhaust, foods,
caffeine, or alcoholic beverages. The term
refers to the reported finding that some
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persons exhibit adverse reactions to chemi-
cals that they formerly did not exhibit and
that others do not exhibit at the doses or
levels administered. This definition is in
contrast to acquired tolerance, e.g., to a
drug, which is defined as reduced effect as
a function of dosage. Masking, discussed in
detail by Miller (6), refers to the hiding or
obfuscation of responses to challenges due
to overlapping of responses to closely
timed exposures, or habituation or acclima-
tization to incitants. Triggering is defined
as the provocation of symptoms by a
chemical stimulus or incitant.
Ultimately it will be important to
answer the question whether exposure to
pesticides, contaminated air in sick build-
ings, or low levels of solvents can initiate
chemical sensitivity. From a public health
and prevention point of view, this question
is paramount.
It may seem logical first to address
the initiation stage in the development of
chemical sensitivity. Practically speaking,
however, triggering should be addressed
first because if challenge studies on trigger-
ing show that most symptoms are psy-
chogenic in nature and not reproducible,
there is less need to study the initiation
phase. The working group suggested three
principal questions for study. The first
two relate to triggering, whereas the final
question explores initiation.
1) Do some individuals experience sensi-
tivity to chemicals at levels of exposure
unexplained by classical toxicological
thresholds and dose-response relation-
ships, and outside normally expected
variation in the population? (Does trig-
gering occur?)
2) Do chemically sensitive subjects exhibit
masking that may interfere with the
reproducibility of their responses to
chemical challenges? (Does masking.
affect responses?)
3) Does chemical sensitivity develop as a
consequence of acute, intermittent, or
continuous exposure to certain sub-
stances? If so, what substances are most
likely to initiate this process? (What
initiates the condition?)
The first question, related to triggering
of symptoms in some individuals, is per-
haps the most fundamental and received
the most attention.
Several experimental considerations
were raised. No attempt was made to
develop a single rigid experimental design.
It was recognized that in the first round of
studies that selection of dependent vari-
ables may need to be open-ended because
of the diversity of clinical presentations and
reported incitants. For example, pul-
monary function testing would be appro-
priate for patients who reported shortness
of breath but not for those whose primary
symptoms were headaches or depression. A
survey of patients' responses to various
exposures could help identify those vari-
ables most likely to be responsive under
challenge conditions. In addition, selection
of exposure agents and concentrations may
need to be tailored to each subject during
pilot studies. Following the first round of
studies, a series of studies will be needed to
focus on selected chemicals and symptoms.
General Approach
and Methodology
During the pilot studies, subjects would be
housed in an environmentally controlled
medical unit (EMU) (1,7,8). Following an
estimated 4- to 7-day period of avoiding
chemical and food incitants (unmasking),
subjects would be challenged with a
selected number of chemicals and foods in a
double-blind, placebo-controlled manner.
The 4- to 7-day window of time estimated
as necessary for unmasking is empirically
derived from clinical observations by
chemically sensitive patients and some of
their physicians. Masking itself requires
testing. A rationale for the 4- to 7-day win-
dow is discussed elsewhere in this issue by
Miller (6). Four to seven days is the aver-
age length of time reported for patients'
symptoms to resolve after they have begun
to avoid incitants. Although the term
detoxification has been used to describe
this process, it has a connotation that dif-
fers from unmasking. For example, for per-
sons dependent on alcohol, detoxification
(sudden cessation of alcohol consumption)
might result in elimination of alcohol from
their systems in a day or more. On the
other hand, it might be several days before
receptors normalized and full recovery
occurred (unmasking).
Testing of the masking concept is
addressed more fully in the following dis-
cussion. Important empirical questions
remain to be answered concerning mask-
ing, questions that may be crucial to the
timing of exposure challenges and to the
outcome of those challenges.
Subject Selection
Subjects should be individuals sharing
recent similar initiating exposures; for
example, persons who became ill during
the remodeling of a building or who were
exposed to organophosphate pesticides
similar to Miller and Mitzel's remodeling-
and organophosphate-exposed groups (9).
Persons with chronic diseases or with sensi-
tivities that developed gradually over their
lifetimes would not be good subjects for
pilot studies because the greater uncertain-
ties about the origins of their illness would
further complicate scientific inquiry.
Subjects who report disruptions in career
and lifestyle by their symptoms and intol-
erances would be preferable for such a
study so as to increase the likelihood of
robust responses with challenges. An alter-
native approach might be to study groups
of individuals representing particular stages
in the evolution of the condition, perhaps
evidenced by different symptom severities
and time elapsed since initiating events.
Subjects 18 to 55 years of age are rec-
ommended. Self-reported symptoms are
not as reliable for children, particularly
those 12 years of age or younger, and after
age 55, end-organ disease and the ability to
endure the rigors of chemical challenges are
of concern. Equal numbers of symptomatic
male and female subjects might be chosen.
Alternatively, selection without regard.to
gender (gender-blind recruitment) could
be implemented. Based upon clinical expe-
rience to date, approximately 80% of sub-
jects might be expected to be women in the
latter case.
Individuals requiring or dependent upon
tobacco, alcohol, or prescription or nonpre-
scription drugs should be excluded as candi-
dates because these substances could alter
responses to challenges. It would be impor-
tant for all participants to be at a "clean base-
line" with respect to chemicals, foods, and
medications before any chemical challenges.
Other reasons for excluding subjects
from study include diagnoses of borderline
personality disorder, schizophrenia, or
other psychiatric disorders that might
interfere with sustained cooperation or the
ability to implement lifestyle changes
should these be found necessary. Structured
clinical interviews and instruments for per-
sonality assessment will help ensure the
consistency of these determinations.
Patients with mild to moderate depression
could participate provided they have no
history of suicide attempts or threats, they
are not taking antidepressants, and stan-
dard suicide precautions are implemented.
It has been reported that after withdrawal
from chemical, food, and drug incitants,
and following some challenges, depression
may increase transiently (7).
There were differing opinions about
including subjects involved in litigation
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or compensation proceedings. Concerns
about the possible impact of litigation
upon subjects' responses further under-
score the need for double-blind, placebo-
controlled challenges.
Control subjects could be selected in
various ways-for example, healthy, nor-
mal individuals; anosmics; or patients with
orthopedic injuries. Matching for age, gen-
der, and education is advisable. Control
subjects can help define the expected
responses of normal individuals in the
unique environment of an EMU regarding
withdrawal, masking, and other parame-
ters. In addition to the use of control sub-
jects, subjects could act as their own
controls, for example, in a repeated mea-
sures experimental design. It is recom-
mended that a repeated measures design be
used both with patients serving as their
own controls and those serving as normal
controls (persons not known to be sensitive
to chemicals) to define the impact of the
EMU and the protocol on both putatively
sensitive and normal individuals.
Experimental Design
The sequence of procedures in a proposed
experiment would be as follows: recruit
subjects and controls; screen both subjects
and controls; make baseline measurements;
conduct open chemical and food challenges;
conduct blind chemical and food challenges
and measure dependent variables; debrief
and reacclimatize participants.
Measurements made on subjects while
still at home before they entered the EMU
might include: volatile organic chemicals
in breath or indoor air in subjects' homes;
self-reported ratings of symptoms using
visual analog scales; an inventory of life
stressors; additional demographic data
including level of education and socioeco-
nomic status (important for selection of
controls); detailed psychosocial, family,
occupational, and environmental histories;
and computerized neurobehavioral batter-
ies of tests to measure cognition and atten-
tion span at baseline. Selected measures
should be repeated following entry into the
EMU, after unmasking, and before and
after challenges.
For all subjects, the EMU experience
would begin with a period of controlled
exposure. To assure that subjects were at a
clean baseline (unmasked) before testing,
they would be housed in a hospital research
area or a wing specially designed to reduce
exposure to volatile organic chemicals,
an EMU (1,7,8). The goal would be to
reduce participants' exposures to airborne
contaminants to the lowest levels practica-
ble. Fragrances, pesticides, disinfectants,
soft plastics, and other chemicals and mate-
rials that emit volatile compounds would
not be allowed in such a facility. Clean air
for breathing would be achieved through
the use of materials and furnishings that do
not emit volatile compounds, state-of-the-
art air filtration for particulates and vapors,
and controlled access to the unit.
The rationale here is that a hospital-
based environmental medical unit would
permit residence for a time sufficient to
allow patients to unmask fully and reach a
clean (asymptomatic or minimally sympto-
matic) baseline. Round-the-clock nursing
and hospital emergency services necessary
to ensure patient safety generally are not
available in conventional exposure cham-
bers. During unmasking and subsequent
challenges, chemically sensitive patients
have been reported to develop bron-
choconstriction, confusion, depression,
and other symptoms that mandate they be
under continuous observation (8).
Testing at admission to the EMU
should include computer-administered
cognitive batteries and subjective symptom
ratings on a visual analog scale. Neuro-
behavioral tests should address subjects'
attention, concentration, memory (verbal
and visual), and general processing effi-
ciency. Computer administration of per-
formance tasks with prior training to
asymptote in order to avoid practice effects
could be performed during the unmasking
period. In addition, odor thresholds, smell
identification ability (UPSIT) (10), and
odor intensity ratings could be evaluated.
Odor thresholds should be determined
using up/down staircasing.
Because it is not feasible to test every
subject with every potential incitant, chal-
lenges could be administered using a
defined panel of substances at entry into
the EMU. This first round of testing
should be conducted using an open chal-
lenge format to ensure that substances and
concentrations selected for later blinded
challenges are those reported to trigger
symptoms. Similarly, open challenges with
placebos should be performed before
administering blinded challenges. This will
help to ensure that for each subject, actives
are truly actives and placebos truly place-
bos, since one person's placebo might be
another's trigger and vice versa. All subse-
quent challenges should be double-blind
and placebo-controlled. Symptoms and
signs are then recorded and observed for
resolution over time.
Following the 4- to 7-day period of
unmasking, blinded challenges should be
conducted using the same incitants used at
admission. This approach to testing sub-
jects-both on entry into the EMU and
after unmasking-could help advance
understanding of the possible effects of
masking upon responses. Ideally there
should be no contact between subjects
before or during testing; however, this
would be very difficult to achieve. The wis-
est option might be to house subjects
together but test them separately.
Statistical considerations are important
in determining the number of repeat chal-
lenges per incitant. Also, there are practical
limits as to the number of challenges
patients can be expected to undergo, par-
ticularly if their symptoms are severe.
Careful consideration should be given to
reacclimatizing subjects to real-world con-
ditions on completion of their evaluation
and before discharge from the EMU. A
protocol might be designed for this pur-
pose that consists of gradual reintroduction
of less problematic triggers.
Even among chemically sensitive
persons exhibiting highly individualized
symptoms in response to many different
incitants, it may be possible to study and
compare subjects and controls in an infor-
mative way. Before subjects enter the
EMU, baseline challenges could be con-
ducted to characterize each subject's inci-
tants and symptoms. Incitants such as
formaldehyde or ethanol that are common
to several groups of subjects may help
define subgroups, as may particular symp-
toms such as breathing difficulties or
gastrointestinal effects.
During the double-blind, placebo-con-
trolled challenges, patients could be asked
to report the severity of their symptoms on
a scale (e.g., a 10-point scale) that would
facilitate comparison of responses between
or among different subjects and controls.
For example, a subject might report symp-
toms of varying severity evoked by five
alternating, sequential administrations of
incitants and placebos to yield the readings:
6/3, 5/2, 7/4, 5/2, and 3/1. Subgroups
exhibiting identical symptoms evoked by
different incitants or affected by the same
incitant but having different symptoms
might be examined in this manner, as well
as persons having different symptoms in
response to different incitants. In each of
these situations, with the subjects acting as
their own controls during administration
of the double-blind, placebo-controlled
challenges, it would be useful to compare
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the ratios of the responses to incitants over
(divided by) the responses to placebos in
the experimental subjects to the corre-
sponding response ratios in the control
group. For example, a control subject
might exhibit the ratios 2/2, 3/2, 3/3, 1/1,
and 2/1 to the five sequential, alternate
administrations of incitants and placebos.
The distribution of the ratios for the exper-
imental subjects could be compared graph-
ically to the distribution of the ratios for
the control group and the response differ-
ences between experimental and control
groups analyzed statistically.
Exposure Variables
Dose Level
Measures of exposure dose could include
dose delivered, breath or blood concen-
trations, and/or amounts appearing in
the urine.
Type of Exposure Administration
Double-blind, placebo-controlled challenges
should be administered, with a 4- to 7-day
interval between challenges of a particular
type. While administration of ascending
concentrations of challenge substances has
advantages in terms of patient safety and
ensuring delivery of an effective dose, such
an approach could lead to short-term toler-
ance (as occurs in drug desensitization pro-
tocols) when, in fact, a single dose on the
high side of the ascent might have provoked
symptoms. The consequences of adminis-
tering various concentrations at various
intervals should be explored further.
Nasal Occlusion
The effects of occluding the nares (using a
nasal clip or Microfoam TM tape [3M
Corporation, St. Paul, MN]) during chal-
lenge compared with no occlusion should
be assessed, given one hypothesis that olfac-
tory-limbic stimulation plays a role in trig-
gering symptoms of chemical sensitivity (5).
Specific Challenge Agents
A number of specific challenge agents were
proposed, including inhalants such as
vanillin/vanilla (no trigeminal stimulation)
and carbon dioxide (trigeminal stimula-
tion); fragrances such as galaxolide (musk),
rose oil and geraniol; low concentrations of
common solvents and indoor air contami-
nants such as ethanol, xylenes, decane,
undecane, toluene, trimethyl benzenes,
ethyl toluene, ethyl benzene, paradichloro-
benzene (mothballs), methyl ethyl ketone,
and acetone; possible controls such as
water, propylene glycol, and light mineral
oil (the appropriateness of each of these as
placebos would be confirmed via open
challenge for each subject); ingestants
administered in the form of capsules or as
frozen slurries with nasal occlusion for
blinding taste; caffeine; monosodium glu-
tamate; various food additives; particular
foods or sugars that evoked symptoms dur-
ing open challenges; possible controls such
as matched slurries or capsules using foods
not associated with symptoms during open
challenge-for example, beef as a control
for pork or oatmeal as a control for corn.
Substances known to bioaccumulate
such as polychlorinated biphenyls and
chlordane should not be used for testing.
The ethics of using certain common house-
hold pesticides even at very low concentra-
tions as challenge substances was discuessed.
Some reports suggest that certain pesticides
might initiate chemical sensitivity in sus-
ceptible persons (4,9). Another consid-
eration is the length of studies and cost
involved in waiting 4 to 7 days between
challenges of a particular type. Chemically
distinct challenges could be administered
in the intervals between challenges of a
given type provided subjects had recovered
fully before each challenge.
Dependent Variables
Dependent variables discussed for possible
use include: duration of response; symp-
toms such as headache, fatigue, myalgias,
and other symptoms rated on visual analog
scales to record severity; ratings on mood
scales such as the Profile of Mood States
(POMS); performance, which includes
such things as computer-administered cog-
nitive batteries (with emphasis on attention
span, memory, and concentration mea-
sures) and balance (posturography); physi-
ological measures which include nasal
resistance, pulmonary function testing such
as peak flow readings and FEV1, blood
pressure, pulse, electrocardiogram, and gal-
vanic skin response; and rheumatological
indices such as rings for measuring finger
joint swelling and dolorimeter readings for
measuring pain.
Brief batteries for specific tasks could
be alternated with continuous perfor-
mance tasks. The duration of any testing
sequence should not exceed about 20 min
to be useful for administration before and
after challenges.
As a practical matter, initial studies
should focus on documenting signs and
symptoms in response to blinded chal-
lenges, rather than costly shot-in-the-dark
attempts to find blood markers or perform
brain imaging.
Ethical Considerations Involving
Human Subjects
Subjects should be counseled about the ini-
tial withdrawal or unmasking phase of their
evaluation and challenge testing during
which symptoms temporarily may increase
in severity. On-site emergency response
capabilities and limitations should be
explained to subjects. If they are found to
be sensitive to particular chemicals or foods
during the study, a transitional "safety net"
for reentry into the "real world" should be
incorporated into the protocol. Upon com-
pletion of the study, participants should
receive any data pertinent to their well-
being, including the results of all chal-
lenges, how to avoid substances to which
they reacted, and how to use air filters
and/or respirators if indicated. As with
all research involving human subjects,
informed consent is required. The consent
should fulfill social responsibility yet avoid
biasing subjects' responses.
The masking hypothesis, the second
question suggested for investigation, could
be tested using an approach similar to that
discussed in question 1. In this case, how-
ever, subjects in the EMU would be chal-
lenged with incitants already known to
provoke significant effects. Changes in the
intensity and duration of symptoms with
sequential challenges administered at vary-
ing intervals-for example, 10 days apart,
7 days, 5 days, 3 days, 2 days, and 1 day-
would be monitored. Questions to be
answered include: At what point does
remasking occur? How far apart should
challenges be spaced to observe the most
robust effect following reexposure? What
are the effects of lengthening or shortening
the time interval between challenges of a
particular type? Answers to these questions
will facilitate the design of future studies.
The third question to be answered con-
cerns whether chemical sensitivity develops
as a consequence of acute, intermittent, or
continuous exposure to certain substances.
If so, which substances are most likely
to initiate this process? If the research
described above uncovered individuals
exhibiting biological sensitivity at levels
unexplained by classical toxicology, then
research into particular mechanisms would
be indicated. An additional task would be
to determine whether and which exposures
initiate chemical sensitivity.
Two basic approaches for examining
question 3 were identified. One approach
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would be to begin with a particular expo-
sure history and try to determine whether
some of those who had been exposed
developed chemical sensitivities, and follow
those who developed chemical sensitivities
prospectively. Examples of selecting on the
basis of exposure history might include
identifying workers or community mem-
bers exposed during a chemical spill or
accident; persons residing in a building or
community during pesticide application;
workers or teachers and school children
exposed in a sick building; patients receiv-
ing a particular anesthetic, implanted
device, or other medical intervention; or
consumers who purchased a particular
product, such as new carpeting.
A second approach to question 3 would
be to choose subjects with particular
medical conditions, diseases, or symptoms
and look for patterns of prior exposure.
Populations of patients with Parkinson's
disease, chronic fatigue syndrome, fibro-
myalgia, asthma, multiple sclerosis, periph-
eral neuropathies, chronic urticaria, chronic
sinusitis, and other conditions might be
queried for chemical sensitivities and any
history of an antecedent chemical exposure
event. Recent work on Parkinson's disease
suggests that living in a rural area and
drinking well water may be risk factors for
this condition (11).
The first approach, that is, tracking
individuals with similar exposure histories
to discover whether any subsequently
develop low-level chemical intolerances,
may prove more fruitful because these study
groups would be relatively homogeneous.
Summary
Understanding toxicant-induced loss of
tolerance or heightened responsiveness to
low-level chemical exposures requires
investigating both the triggering of symp-
toms and the initiation of chemical sensi-
tivity in affected persons. Because of the
wide variety of symptoms attributed to
chemical sensitivity and the fact that chem-
ical sensitivity could represent a general
class or family of disorders, traditional
population-based epidemiologic approaches
are unlikely to be helpful in documenting
the triggering stages. Instead, individual
double-blind, placebo-controlled chal-
lenges in which subjects act as their own
controls are needed. A control group should
also be investigated in parallel fashion and
is particularly important for defining the
effects of the EMU on responses. Because
of its possible critical role, masking must
also be investigated.
On the other hand, traditional popula-
tion-based studies may be useful in study-
ing the initiation of chemical sensitivity.
Such studies are most likely to be success-
ful when as many confounding variables
as possible are minimized. A particularly
useful strategy may be to select persons
for study who shared the same or similar
exposures preceding onset of their illnesses.
The induction of chemical sensitivity is
addressed in this paper as a third but
equally important research direction, par-
ticularly in the context of preventing new
cases of chemical sensitivity.
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